Tekla Capital Management’s United Therapeutics UTHR Stock Holding History

Tekla Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$9.15M	Sell	41,465 -19,735	-32%	-$4.37M	0.36%	63
2023 Q1	$13.7M	Sell	61,200 -53,877	-47%	-$13.3M	0.52%	43
2022 Q4	$32M	Sell	115,077 -2,300	-2%	-$581K	1.21%	25
2022 Q3	$24.6M	Buy	117,377 +45,171	+63%	+$10.1M	1.01%	30
2022 Q2	$17M	Hold	72,206	–	–	0.67%	38
2022 Q1	$13M	Sell	72,206 -29,531	-29%	-$5.63M	0.45%	53
2021 Q4	$22M	Sell	101,737 -43,203	-30%	-$8.48M	0.71%	41
2021 Q3	$26.8M	Buy	144,940 +5,502	+4%	+$1.08M	0.86%	34
2021 Q2	$25M	Buy	139,438 +75,925	+120%	+$14.5M	0.81%	31
2021 Q1	$10.6M	Hold	63,513	–	–	0.37%	71
2020 Q4	$9.64M	Hold	63,513	–	–	0.34%	82
2020 Q3	$6.42M	Hold	63,513	–	–	0.24%	92
2020 Q2	$7.68M	Hold	63,513	–	–	0.29%	73
2020 Q1	$6.02M	Buy	63,513 +9,419	+17%	+$895K	0.27%	73
2019 Q4	$4.76M	Hold	54,094	–	–	0.18%	106
2019 Q3	$4.31M	Hold	54,094	–	–	0.19%	91
2019 Q2	$4.22M	Buy	54,094 +12,833	+31%	+$1.2M	0.17%	99
2019 Q1	$4.84M	Hold	41,261	–	–	0.2%	96
2018 Q4	$4.49M	Hold	41,261	–	–	0.19%	89
2018 Q3	$5.28M	Hold	41,261	–	–	0.19%	89
2018 Q2	$4.67M	Hold	41,261	–	–	0.18%	95
2018 Q1	$4.64M	Buy	41,261 +25,041	+154%	+$3.18M	0.18%	94
2017 Q4	$2.4M	Sell	16,220 -27,741	-63%	-$3.53M	0.09%	120
2017 Q3	$5.15M	Hold	43,961	–	–	0.18%	89
2017 Q2	$5.7M	Hold	43,961	–	–	0.21%	84
2017 Q1	$5.95M	Sell	43,961 -49,139	-53%	-$7.44M	0.23%	81
2016 Q4	$13.4M	Hold	93,100	–	–	0.57%	40
2016 Q3	$11M	Hold	93,100	–	–	0.42%	57
2016 Q2	$9.86M	Hold	93,100	–	–	0.4%	60
2016 Q1	$10.4M	Hold	93,100	–	–	0.44%	57
2015 Q4	$14.6M	Sell	93,100 -89,500	-49%	-$13M	0.53%	39
2015 Q3	$24M	Buy	+182,600	New	+$29.3M	0.86%	23

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Tekla Capital Management's UTHR Position: Q2 2023 in Review

Tekla Capital Management reduced its United Therapeutics (UTHR) stake by 32% in Q2 2023, selling an estimated $4.37M and leaving 41,465 shares worth $9.15M. The position accounts for 0.36% of the portfolio, ranked #63.

Tekla Capital Management first reported a position in UTHR in Q3 2015 and has held it in 32 quarters since. The position peaked at $32M in Q4 2022. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Tekla Capital Management held 41,465 shares of United Therapeutics worth $9.15M as of Q2 2023.
Tekla Capital Management sold 19,735 United Therapeutics shares in Q2 2023, an estimated $4.37M.
United Therapeutics made up 0.36% of Tekla Capital Management's portfolio in Q2 2023, its #63 holding.
Tekla Capital Management first reported a position in United Therapeutics in Q3 2015 and has held it in 32 quarters since.
Tekla Capital Management's United Therapeutics position peaked at $32M in Q4 2022.
475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.